Back

Genomic analysis of Mycobacterium brumae sustains its nonpathogenic and immunogenic phenotype

Renau-Minguez, C.; Herrero-Abadia, P.; Sentandreu, V.; Ruiz-Rodriguez, P.; Torrents, E.; Chiner-Oms, A.; Torres-Puente, M.; Comas Espadas, I.; Julian, E.; Coscolla, M.

2022-12-02 genetics
10.1101/2022.12.01.518671 bioRxiv
Show abstract

M. brumae is a rapid-growing, non-pathogenic Mycobacterium species, originally isolated from environmental and human samples in Barcelona, Spain. M. brumae is not pathogenic and its in vitro phenotype and immunogenic properties have been well characterized. However, the knowledge of its underlying genetic composition is still incomplete. In this study, we first describe the 4 Mb genome of the M. brumae type strain ATCC 51384T assembling PacBio reads, and second, we assess the low intraspecies variability by comparing the type strain with Illumina reads from three additional strains. M. brumae genome is composed of a circular chromosome with a high GC content of 69.2 % and containing 3,791 CDSs, 97 pseudogenes, one prophage and no CRISPR loci. M. brumae has shown no pathogenic potential in in vivo experiments, and our genomic analysis confirms its phylogenetic position with other non-pathogenic and rapid growing mycobacteria. Accordingly, we determined the absence of virulence related genes, such as ESX-1 locus and most PE/PPE genes, among others. Although immunogenic potential of M. brumae was proved to be as high as Mycobacterium bovis BCG, the only mycobacteria licensed to treat cancer, the genomic content of M. tuberculosis T cell and B cell antigens in M. brumae is considerably lower than those of M. bovis BCG. Overall, this work provides relevant genomic data on one of the species of the mycobacterial genus with high therapeutic potential.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Frontiers in Cellular and Infection Microbiology
98 papers in training set
Top 0.1%
22.7%
2
Scientific Reports
3102 papers in training set
Top 2%
14.8%
3
Frontiers in Medicine
113 papers in training set
Top 0.6%
6.4%
4
Frontiers in Microbiology
375 papers in training set
Top 2%
4.9%
5
Microbial Genomics
204 papers in training set
Top 0.5%
3.9%
50% of probability mass above
6
PLOS ONE
4510 papers in training set
Top 39%
3.6%
7
Nature Communications
4913 papers in training set
Top 39%
3.6%
8
Microbiology Spectrum
435 papers in training set
Top 0.8%
3.6%
9
mBio
750 papers in training set
Top 4%
3.6%
10
Antimicrobial Agents and Chemotherapy
167 papers in training set
Top 0.8%
2.4%
11
International Journal of Molecular Sciences
453 papers in training set
Top 6%
1.9%
12
eLife
5422 papers in training set
Top 41%
1.7%
13
mSphere
281 papers in training set
Top 3%
1.7%
14
mSystems
361 papers in training set
Top 6%
1.2%
15
The Lancet Microbe
43 papers in training set
Top 0.8%
1.2%
16
Communications Biology
886 papers in training set
Top 17%
1.0%
17
The Journal of Infectious Diseases
182 papers in training set
Top 4%
1.0%
18
Virulence
21 papers in training set
Top 0.4%
0.8%
19
BMC Genomics
328 papers in training set
Top 5%
0.8%
20
Journal of Infection
71 papers in training set
Top 3%
0.8%
21
Nucleic Acids Research
1128 papers in training set
Top 17%
0.8%
22
Genome Medicine
154 papers in training set
Top 8%
0.8%
23
Journal of Advanced Research
15 papers in training set
Top 1%
0.6%
24
PLOS Pathogens
721 papers in training set
Top 10%
0.6%
25
Tuberculosis
11 papers in training set
Top 0.3%
0.6%
26
BMC Infectious Diseases
118 papers in training set
Top 7%
0.5%
27
BMC Biology
248 papers in training set
Top 7%
0.5%
28
Clinical Chemistry
22 papers in training set
Top 1%
0.5%
29
Frontiers in Immunology
586 papers in training set
Top 10%
0.5%
30
One Health
29 papers in training set
Top 2%
0.5%